Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon therapy for hepatitis C

C Trépo1, F Habersetzer, F Bailly

  • 1Service d'Hépato-gastroentérologie, Hopital Hotel-Dieu, Lyon, France.

Antiviral Research
|July 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk of hepatitis B surface antigen seroreversion after allogeneic hematopoietic SCT.

Bone marrow transplantation·2010
Same author

Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.

Antimicrobial agents and chemotherapy·2010
Same author

European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes.

Journal of clinical microbiology·2006
Same author

In vitro characterization of the anti-hepatitis B virus activity and cross-resistance profile of 2',3'-dideoxy-3'-fluoroguanosine.

Antimicrobial agents and chemotherapy·2006
Same author

Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection.

Antimicrobial agents and chemotherapy·2004
Same author

Animal models for the study of HBV infection and the evaluation of new anti-HBV strategies.

Journal of gastroenterology and hepatology·2003
Same journal

The anti-respiratory syncytial virus activity of biochemicals from Pyrola incarnata.

Antiviral research·2026
Same journal

Ginsenoside Rb2-based inactivation enables a Zika vaccine that maintains pregnancy and protects offspring against virus.

Antiviral research·2026
Same journal

ITGA4 drives pathogenesis of flavivirus and inhibition of it protects mice against Japanese encephalitis virus infection.

Antiviral research·2026
Same journal

Corrigendum to "A virus-like particle candidate vaccine based on CRISPR/Cas9 gene editing technology elicits broad-spectrum protection against SARS-CoV-2" [Antivir. Res. 225 (2024) 105854].

Antiviral research·2026
Same journal

Effects of RNA polymerase inhibitors on nucleotidylylation of human norovirus VPg.

Antiviral research·2026
Same journal

Human monoclonal antibodies from donors vaccinated with recombinant vaccinia vaccine targeting A35 and B6 effectively inhibit orthopoxvirus spread and infection.

Antiviral research·2026
See all related articles

Recombinant alpha interferon therapy for hepatitis C virus (HCV) shows moderate response rates, with patient selection and virological markers being crucial for successful treatment outcomes and monitoring. Relapse is common, highlighting the need for optimized therapeutic strategies.

Area of Science:

  • Hepatology and Viral Gastroenterology
  • Immunotherapy and Molecular Virology

Background:

  • Recombinant alpha interferon therapy initially normalized alanine aminotransferase (ALT) in approximately 50% of hepatitis C virus (HCV) patients.
  • Half of responding patients relapsed within six months post-treatment, indicating limitations of early interferon regimens.
  • Initial efficacy assessments relied on ALT normalization and histological scores, predating widespread use of virological markers.

Purpose of the Study:

  • To evaluate the critical role of dose and duration in interferon therapy response.
  • To explore the impact of patient selection and hepatitis C virus (HCV) characteristics on treatment outcomes.
  • To underscore the importance of virological markers for assessing HCV infection and guiding therapy.

Main Methods:

Related Experiment Videos

  • Analysis of initial clinical trial data using ALT normalization and histological scores.
  • Incorporation of virological markers (HCV RNA levels) to assess treatment efficacy.
  • Comparative analysis of response rates based on patient factors (cirrhosis, HCV RNA levels) and HCV genotype.

    • Main Results:

    • Higher doses and longer durations of interferon therapy were suggested to improve efficacy.
    • Patient selection proved critical, with better responses observed in patients without cirrhosis and with low HCV RNA.
    • Hepatitis C virus (HCV) genotype significantly influenced response rates.
    • Clinical improvements correlated with decreased or undetectable HCV RNA in serum and liver.

    Conclusions:

    • Virological markers are essential for accurate assessment of HCV infection and therapeutic monitoring.
    • Optimizing patient selection and considering HCV genotype are crucial for improving interferon therapy outcomes.
    • Current interferon regimens may require adjustments in dose, duration, and patient stratification for enhanced efficacy.